ITeos, GSK discontinue lung cancer therapy development-February 2024-www.financetom.com

ITeos, GSK discontinue lung cancer therapy development

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

ITeos, GSK discontinue lung cancer therapy development

May 26, 2025 6:40 AM

May 13 (Reuters) - iTeos Therapeutics ( ITOS ) and

partner GSK said on Tuesday that they terminated the

development of their experimental lung cancer therapy after its

failure to significantly improve progression free survival in a

mid-stage trial.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Anil

D'Silva)

Previous page： SL Green Realty Signs Lease Agreement with Verition Group Next page： Telesat and Airbus Join Forces to Integrate Telesat Lightspeed Services into HBCplus portfolio

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

SL Green Realty Signs Lease Agreement with Verition Group

Nov 3, 2024

08:07 AM EDT, 10/28/2024 (MT Newswires) -- SL Green Realty ( SLG/PI ) said Monday it signed a 10-year lease agreement with hedge fund Verition Group NY for 72,515 square feet, increasing building occupancy to 92.5%. Verition will move from the 35th floor to the 14th and 15th floors, expanding its space by 34,413 square feet, SL Green said. Redevelopment...

Telesat and Airbus Join Forces to Integrate Telesat Lightspeed Services into HBCplus portfolio

Nov 3, 2024

07:47 AM EDT, 10/28/2024 (MT Newswires) -- Telesat ( TSAT ) a satellite operator, on Monday said it has signed a Memorandum of Understanding (MOU) with Airbus SAS to collaborate on the integration of the Telesat Lightspeed low earth orbit (LEO) network within the Airbus HBCplus Ka-band solution portfolio. The two companies will work together to address user terminal integration...

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion in Cash

Nov 3, 2024

08:14 AM EDT, 10/28/2024 (MT Newswires) -- AbbVie ( ABBV ) said Monday it has reached a definitive agreement to acquire Aliada Therapeutics, a biotechnology company, for $1.4 billion in cash. The deal is expected to close in Q4, subject to regulatory approvals and other customary closing conditions. Price: 187.99, Change: +0.14, Percent Change: +0.07 ...

CenterPoint misses third-quarter estimates on higher costs, Beryl-related outages

Nov 3, 2024

Oct 28 (Reuters) - Electric and gas utility CenterPoint Energy ( CNP ) on Monday reported third-quarter profit that missed Wall Street estimates, hurt by higher maintenance costs and lower revenue from its electric segment due to Hurricane Beryl. The company said it has appointed Don Daigler to lead its emergency preparedness and response efforts, following criticism for its power...